Pfizer Questions Drug ‘Total Content’ in Biosimilar Guidance

Drug Industry Daily
A A
Pfizer asked the FDA to clarify the term “total content” in its draft guidance for biosimilar development, for demonstrating that a drug and a reference product have the same strength.

To View This Article:

Login

Subscribe To Drug Industry Daily